IMR Press / CEOG / Volume 12 / Issue 1-2 / pii/1634257693823-1264762858

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Benefits of vaginal estriol cream combined with clonidine HCL for menopausal syndrome treatment
Show Less
1 Special Outpatient Clinic – “Mishmar Hayarden”, Dan District (Israel)
Clin. Exp. Obstet. Gynecol. 1985, 12(1-2), 1–2;
Published: 10 March 1985
Abstract

In a group of 25 post menopausal women mean age 57.2 years, treatment with Estriol vagina cream (Ovestin cream from Organon-Holland) gives rise (but within normal limits) to cholesterol, triglycerides and HDL-cholesterol, the protective factor against M. I. A rise in glycohemoglobin (HbA1C) statisticaly significant was noted, as a sign of slight glucose intolerance, but in no case was there a diabetic pattern. Vaginal Estriol cream was able to prevent osteoporosis. After a few weeks of treatment urinary calcium/creatinine ratio decreased. In the light of our own findings, Ovestin being a weak estrogen does not induce endometrial proliferation or breakthrough bleeding and does not modify the blood biochemistry, and can be recommended for postmenopausal syndrome even in familial hyperlipidemia diabetes, and for prevention of osteoporosis.
Share
Back to top